You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. High-Repetition-Rate Pump Sources Tailored for High-Purity Entanglement Generation

    SBC: ADVR, INC.            Topic: T8

    This Phase I SBIR will lead to the development of a bandwidth tailored pump source for high purity photon pair generation. Spontaneous parametric down conversion can be used to generate high purity photon pairs at wavelengths of interest to NASA and the broader scientific community. However, these sources are highly dependent on pulsed pump laser parameters. Traditional pulsed laser sources are la ...

    STTR Phase I 2023 National Aeronautics and Space Administration
  7. High-purity, high-rate, photon pair source for space-based entanglement distribution

    SBC: ADVR, INC.            Topic: T5

    The overall goal of this NASA effort is to develop and deliver efficient, single-pass quantum optical waveguide sources generating high purity polarization entangled photon pairs for use in high-rate long-distance links. The key innovation in this effort is the use of efficient, low-loss spontaneous parametric down conversion (SPDC) waveguides in combination with apodized gratings to tailor the op ...

    STTR Phase II 2022 National Aeronautics and Space Administration
  8. Tunable Narrow-Band Bi-Photon Source in IR Spectral Region for Calibration of High-Performance Transition-Edge Sensors

    SBC: ADVR, INC.            Topic: T8

    The overall goal of this NASA STTR mult-phase effort is to develop a compact fully integrated tunable narrowband bi-photon source operating in the visible/IR spectral region for calibration and characterization of high-performance transition-edge sensors (TES) arrays under development at NASA Goddard as well as other research facilities throughout U.S.nbsp; The key innovation in this effort is com ...

    STTR Phase II 2022 National Aeronautics and Space Administration
  9. High brightness, waveguide-based IR quantum light sources

    SBC: ADVR, INC.            Topic: T8

    Quantum light sources are a critical need for NASA and the broader scientific community. The proposed program will develop ultra-high brightness, low loss, integrated quantum light sources in the IR spectral regime using waveguide-based technology.

    STTR Phase I 2022 National Aeronautics and Space Administration
  10. Mitofusin Agonists to Treat Neurodegenerative Disease

    SBC: Mitochondria in Motion, Inc.            Topic: 104

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government